Developing Best in Class Retinal Medicines

Oligasis is a biopharmaceutical company specializing in the discovery and development of best in class retinal medicines for wet and dry forms of age-related macular degeneration (AMD).

Our pipeline utilizes our Bioconjugate technology, a proprietary product platform invented at Oligasis that combines state of the art biologics design with next generation phosphorylcholine Biopolymers.

Our pipeline products are safe and potent antibody drug conjugates with ocular half-lives four to five times longer than today's marketed products.

Our lead program is a first in class single agent dual angiogenesis inhibitor biologic for wet AMD dosed quarterly or less frequent. Our second program is a first in class complement inhibitor biologic for intermediate dry AMD dosed quarterly or less frequent.

:: Extreme Biocompatibility  

Science Journal Articles

The fundamental science of water structuring drives the extreme biocompatibility of Oligasis' biopolymers and is the subject of recent Science articles:

Chen M et al (2009) Lubrication at Physiological Pressures by Polyzwitterionic Brushes. Science 323, 1698.

Raviv U et al (2002) Fluidity of Bound Hydration Layers. Science 297, 1540.

Clinically Proven Precedent

Oligasis’ technology starts with well-established principles, proven in the following marketed medical devices, and reinvents them entirely for application to injectable medicines:

CooperVision's Proclear contact lenses.

Medtronic's Endeavor drug-eluting coronary stent.

Sorin's PrimO2X oxygenators and perfusion tubing systems.